OnCo

Create your OnCo account

One account keeps your watchlist, saved views and cancer choice in sync across your devices, and lets OnCo alert you when a trial or treatment you follow changes. No password: we email you a sign-in link.

Account creation is being switched on. Until then, press Watch on any page and your list stays in this browser.

Living with cancer· Appointment prep

Appointment sheet: Imatinib-resistant GIST

One page to bring and write on: your details, the questions for Imatinib-resistant GIST plus your own, the words you may hear, what to bring, the treatments the standard of care names, and room for the answers and agreed next steps. What you type stays in this browser. Print it or save it as a PDF. New to all this? Start with the first 60 days. Orientation, not medical advice.

Tick the questions to print

All of this cancer's questions start ticked. Untick what does not apply; ticks are kept in this browser. .

Your own questions

Shared with the prep pack, so questions you add there appear here too.

Print or save as PDF

Use (or Ctrl+P, Cmd+P on a Mac). To keep a copy, choose Save as PDF as the destination in the print dialog. Only the sheet prints; the controls stay on screen. Your typed notes print where you typed them; empty fields print as ruled lines to write on.

Appointment sheet

Imatinib-resistant GIST

Prepared with OnCo (onco.cc/prep/gist-imatinib-resistant/). Orientation, not medical advice; your team knows your case.

My details

Name
Date of appointment
Hospital and clinician
Who is coming with me

What I know, what is unclear, changes to discuss

Saved in this browser
What I know so far
What is unclear to me
Changes since last time

My questions

19 on the sheet
Newly diagnosed
  1. 1.What is my exact diagnosis, stage, and grade, and which tests established them?
  2. 2.Which biomarkers have been tested on my tumour (for example Secondary KIT mutations by circulating tumour DNA, Primary KIT or PDGFRA mutation, Growth within a treated lesion on CT, Imatinib plasma level to exclude underdosing, Thyroid function and blood pressure on sunitinib and regorafenib), and what were the results?
  3. 3.Which subtype is my cancer, and does that change the recommended treatment?
  4. 4.Is germline (inherited) genetic testing recommended for me or my family?
Progression on imatinib 400 mg
  1. 5.For my situation (progression on imatinib 400 mg), which of the standard options do you recommend and why?
  2. 6.Am I a candidate for Imatinib, and what side effects should I expect?
Second line
  1. 7.For my situation (second line), which of the standard options do you recommend and why?
  2. 8.Am I a candidate for Sunitinib, Ripretinib, and what side effects should I expect?
  3. 9.How do the results of A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib and INSIGHT apply to someone like me?
Third line
  1. 10.For my situation (third line), which of the standard options do you recommend and why?
  2. 11.Am I a candidate for Regorafenib, and what side effects should I expect?
Fourth line and beyond
  1. 12.For my situation (fourth line and beyond), which of the standard options do you recommend and why?
  2. 13.Am I a candidate for Ripretinib, Imatinib, IDRX-42 or related drugs, and what side effects should I expect?
  3. 14.How do the results of INVICTUS apply to someone like me?
Any stage
  1. 15.Are there clinical trials I could join, for example of INSIGHT, IDRX-42, NB003, Bezuclastinib?
  2. 16.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
  3. 17.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
  4. 18.I read that “Polyclonal resistance means no single inhibitor covers every metastasis”. How does that affect my plan?
  5. 19.I read that “Each later line adds months, not years, and toxicity accumulates”. How does that affect my plan?

Tests and results to bring

Biomarker results to ask for: Secondary KIT mutations by circulating tumour DNA (exons 13, 14, 17, 18), Primary KIT or PDGFRA mutation (exon 11 versus 9 versus D842V), Growth within a treated lesion on CT (nodule within a mass), Imatinib plasma level to exclude underdosing, Thyroid function and blood pressure on sunitinib and regorafenib.

Scans and tests linked to this cancer: Liquid biopsy (ctDNA).

Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.

The treatments I may be offered

From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.

Answers and next steps

Saved in this browser
What I was told
Agreed next steps, dates and who to call